Javascript must be enabled to continue!
Abstract DP-009: FULL-TERM BIRTHS ARE PROTECTIVE FOR OVARIAN CANCER – WHAT ABOUT INCOMPLETE PREGNANCIES?
View through CrossRef
Abstract
BACKGROUND: Ovarian cancer is associated with reproductive and hormonal factors including parity, breastfeeding, and use of oral contraceptives. However, the effect of incomplete pregnancies, including both induced and spontaneous abortions, is unclear. The most recent assessments of this association include analyses of two Australian case-control studies and the European Prospective Investigation into Cancer and Nutrition (EPIC) study in which both report no significant association between incomplete pregnancies and risk of ovarian cancer. However, a review of these findings and those included in a systematic review are suggestive of an overall protective effect among women who have had an incomplete pregnancy compared to those who have not.
METHODS: To study the incomplete pregnancy-ovarian cancer association in detail, we pooled epidemiologic data from 16 population-based case-control studies from the Ovarian Cancer Association Consortium (OCAC). An incomplete pregnancy was defined as any pregnancy lasting fewer than six months in duration that did not result in a live birth. The effects of ever having an incomplete pregnancy as well as the number of incomplete pregnancies were evaluated using conditional logistic regression after considering potential confounders. Histotype-specific analyses were also conducted to determine the association between incomplete pregnancies and high-grade serous, low-grade serous, mucinous, endometrioid, and clear cell ovarian cancer.
RESULTS: A total of 11,217 ovarian cancer cases and 18,588 controls was included in our analysis. We found that women who ever had an incomplete pregnancy had a 17% decreased risk of ovarian cancer compared to those who had not (95% CI 0.78-0.87). Risk of ovarian cancer also decreased with increasing number of incomplete pregnancies (p-trend<0.001). When the association with ever having an incomplete pregnancy was examined by histotype, the protective association was strongest for clear cell ovarian cancer (OR=0.55, 95% CI 0.46-0.66) and less apparent for high-grade serous and mucinous ovarian cancers (OR=0.94, 95% CI 0.88-1.01 and OR=0.89, 95% CI 0.74-1.07, respectively). The same patterns are observed for full-births.
CONCLUSIONS: Incomplete pregnancies appear to be associated with a decreased risk of ovarian cancer, particularly for the clear cell histotype. Full births are more protective than incomplete pregnancies. However, these findings suggest that the hormonal milieu during pregnancies of short gestation may be sufficient to confer some protection against ovarian carcinogenesis.
Citation Format: Alice W. Lee, Stacey Rosenzweig, Penelope Webb, Malcolm C. Pike, Celeste Leigh Pearce on behalf of the Ovarian Cancer Association Consortium.. FULL-TERM BIRTHS ARE PROTECTIVE FOR OVARIAN CANCER – WHAT ABOUT INCOMPLETE PREGNANCIES? [abstract]. In: Proceedings of the 12th Biennial Ovarian Cancer Research Symposium; Sep 13-15, 2018; Seattle, WA. Philadelphia (PA): AACR; Clin Cancer Res 2019;25(22 Suppl):Abstract nr DP-009.
American Association for Cancer Research (AACR)
Title: Abstract DP-009: FULL-TERM BIRTHS ARE PROTECTIVE FOR OVARIAN CANCER – WHAT ABOUT INCOMPLETE PREGNANCIES?
Description:
Abstract
BACKGROUND: Ovarian cancer is associated with reproductive and hormonal factors including parity, breastfeeding, and use of oral contraceptives.
However, the effect of incomplete pregnancies, including both induced and spontaneous abortions, is unclear.
The most recent assessments of this association include analyses of two Australian case-control studies and the European Prospective Investigation into Cancer and Nutrition (EPIC) study in which both report no significant association between incomplete pregnancies and risk of ovarian cancer.
However, a review of these findings and those included in a systematic review are suggestive of an overall protective effect among women who have had an incomplete pregnancy compared to those who have not.
METHODS: To study the incomplete pregnancy-ovarian cancer association in detail, we pooled epidemiologic data from 16 population-based case-control studies from the Ovarian Cancer Association Consortium (OCAC).
An incomplete pregnancy was defined as any pregnancy lasting fewer than six months in duration that did not result in a live birth.
The effects of ever having an incomplete pregnancy as well as the number of incomplete pregnancies were evaluated using conditional logistic regression after considering potential confounders.
Histotype-specific analyses were also conducted to determine the association between incomplete pregnancies and high-grade serous, low-grade serous, mucinous, endometrioid, and clear cell ovarian cancer.
RESULTS: A total of 11,217 ovarian cancer cases and 18,588 controls was included in our analysis.
We found that women who ever had an incomplete pregnancy had a 17% decreased risk of ovarian cancer compared to those who had not (95% CI 0.
78-0.
87).
Risk of ovarian cancer also decreased with increasing number of incomplete pregnancies (p-trend<0.
001).
When the association with ever having an incomplete pregnancy was examined by histotype, the protective association was strongest for clear cell ovarian cancer (OR=0.
55, 95% CI 0.
46-0.
66) and less apparent for high-grade serous and mucinous ovarian cancers (OR=0.
94, 95% CI 0.
88-1.
01 and OR=0.
89, 95% CI 0.
74-1.
07, respectively).
The same patterns are observed for full-births.
CONCLUSIONS: Incomplete pregnancies appear to be associated with a decreased risk of ovarian cancer, particularly for the clear cell histotype.
Full births are more protective than incomplete pregnancies.
However, these findings suggest that the hormonal milieu during pregnancies of short gestation may be sufficient to confer some protection against ovarian carcinogenesis.
Citation Format: Alice W.
Lee, Stacey Rosenzweig, Penelope Webb, Malcolm C.
Pike, Celeste Leigh Pearce on behalf of the Ovarian Cancer Association Consortium.
FULL-TERM BIRTHS ARE PROTECTIVE FOR OVARIAN CANCER – WHAT ABOUT INCOMPLETE PREGNANCIES? [abstract].
In: Proceedings of the 12th Biennial Ovarian Cancer Research Symposium; Sep 13-15, 2018; Seattle, WA.
Philadelphia (PA): AACR; Clin Cancer Res 2019;25(22 Suppl):Abstract nr DP-009.
Related Results
Safety and Efficacy of Atezolizumab in Ovarian Cancer
Safety and Efficacy of Atezolizumab in Ovarian Cancer
Abstract
Introduction
Although the efficacy of PD-L1 blockade has been evaluated in analyses that combine pharmacologically distinct antibodies, the specific efficacy and safety of...
Abstract IA31: Molecular epidemiology of ovarian cancer
Abstract IA31: Molecular epidemiology of ovarian cancer
Abstract
Epithelial ovarian cancer (EOC) accounts for 5% of all cancer deaths and is the fifth leading cause of cancer death in women in the United States. While the...
Abstract B8: Molecular subtyping of epithelial ovarian cancer reveals connections to intrinsic breast cancer subtypes
Abstract B8: Molecular subtyping of epithelial ovarian cancer reveals connections to intrinsic breast cancer subtypes
Abstract
Aim: Epithelial ovarian cancer is one of the most lethal female cancers. It is a heterogeneous group of neoplasms and the different histologic subtypes are ...
Abstract 2208: Clinicopathological and genetic study of ovarian cancer in Algerian women: First report
Abstract 2208: Clinicopathological and genetic study of ovarian cancer in Algerian women: First report
Abstract
Background: Ovarian cancer represents the fourth most common cause of mortality among Algerian women. Of all gynecological malignancies, ovarian cancer caus...
Abstract B81: Changing fertility factors affecting breast cancer in the Bahamas
Abstract B81: Changing fertility factors affecting breast cancer in the Bahamas
Abstract
Introduction: There are many factors that affect breast and ovarian cancer incidence. Genetics, obesity, parity, age at menarche, age at first pregnancy, an...
Abstract 4998: Lipolysis-stimulated lipoprotein receptor (LSR) can be a novel therapeutic target of ovarian cancer
Abstract 4998: Lipolysis-stimulated lipoprotein receptor (LSR) can be a novel therapeutic target of ovarian cancer
Abstract
Objective:Ovarian cancer is the most lethal gynecological malignancy. Five-year survival of advanced ovarian cancer patients remains less than 50% and the m...
P–688 Assessment of ovarian vascularity by three-dimensional vaginal power Doppler on day two of menstrual cycle to predict the number of mature eggs collected
P–688 Assessment of ovarian vascularity by three-dimensional vaginal power Doppler on day two of menstrual cycle to predict the number of mature eggs collected
Abstract
Study question
Could ovarian vascularity indices, measured by 3-dimensional (3D) vaginal power Doppler, predict the num...
Abstract 875: PAX8 protein detection in serum of patients with serous ovarian cancer
Abstract 875: PAX8 protein detection in serum of patients with serous ovarian cancer
Abstract
Introduction: The paired-box (PAX) genes encode a family of transcription factors (TFs) with critical roles in the formation of tissues and organs during em...

